The Latest Breaking News from Novo Nordisk

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

The firm also named Maziar Mike Doustdar as its new CEO on Tuesday, after a gloomy financial forecast spooked investors.

Novo CEO ousted in May, in place until successor named

In a letter to the U.S. Food and Drug Administration (FDA) Commissioner Marty Makary on Friday, over 80 bipartisan members asked the agency to stop counterfeit and copycat versions of GLP-1 drugs like Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide) and Eli Lilly and Co.’s (NYSE:LLY) Zepbound from flooding the market.

The Novo Nordisk A/S (NYSE:NVO) attempt to block Mylan Pharmaceuticals from launching a generic version of its weight-loss drug Wegovy hit a major obstacle as the court ruled in Mylan's favor on key infringement claims related to U.S. Patent No. 9,764,003.

Hims Hers Health, Inc. (NYSE:HIMS) shares are trading 16% higher Wednesday, adding to gains of more than 35% over the past month. Here’s a look at what’s going on.

As the Donald Trump administration plans up to 200% tariffs on pharmaceutical companies, Emily Field, head of European pharma research at Barclays, has said that it’s hard to predict which firm would be affected the most by these tariffs, except for Novo Nordisk A/S (NYSE:NVO).

Hims & Hers stock dipped after Novo Nordisk pulled back its partnership for a weight loss drug distribution, though that may not mean much.

40 pictures showing how people looked before and after choosing Ozempic as a weight loss solution.